Restricted accessBrief reportFirst published online 2024-10
Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm,Double-Blind,Phase III,Multicenter,Randomized Clinical Trial
Sleep disturbance has a prevalence of 30–78% in patients with advanced cancer. While pharmacotherapy is common, randomized controlled studies (RCTs) investigating available agents are limited. This study examines the efficacy and safety of temazepam or melatonin versus placebo for sleep in advanced cancer.
Methods:
This is a multicenter, randomized, double-blind, placebo-controlled study of temazepam, melatonin prolonged release (PR) or placebo for insomnia in patients with advanced cancer, and an insomnia severity index (ISI) score of >11.
Results:
Twenty-one participants were randomized: nine to temazepam, eight to melatonin, and four to placebo. Baseline characteristics between groups were similar. The adjusted mean difference in day 8 ISI score versus placebo was −9.1 (95% confidence interval [CI] −17.5, 0.7, p = 0.04) for temazepam and −9.6 (95% CI −18,−1.2, p = 0.03) for melatonin PR. There was no improvement in global quality of life. Both agents were well tolerated.
Conclusion:
Temazepam and melatonin PR were associated with a clinically significant improvement in patient-reported insomnia severity compared with placebo. Findings need confirmation with larger patient numbers.
Get full access to this article
View all access options for this article.
References
1.
MercadanteS, AdileC, FerreraP, et al.Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. Support Care Cancer, 2017; 25(4):1301–1306.
2.
MercadanteS, AielliF, AdileC, et al.Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manage, 2015; 50(6):786–792.
3.
MercadanteS, GirelliD, CasuccioA. Sleep disorders in advanced cancer patients: Prevalence and factors associated. Support Care Cancer, 2004; 12(5):355–359.
4.
MercadanteS, ValleA, CartoniC, et al.Insomnia in patients with advanced lung cancer admitted to palliative care services. Int J Clin Pract, 2021; 75(10):e14521.
5.
SavardJ, MorinCM. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol, 2001; 19(3):895–908.
6.
DavidsonJR, MacLeanAW, BrundageMD, et al.Sleep disturbance in cancer patients. Soc Sci Med, 2002; 54(9):1309–1321.
7.
KayeJ, KayeK, MadowL. Sleep patterns in patients with cancer and patients with cardiac disease. J Psychol, 1983; 114(1st Half):107–113.
8.
EspieCA, FlemingL, CassidyJ, et al.Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol, 2008; 26(28):4651–4658.
9.
GraciG. Pathogenesis and management of cancer-related insomnia. J Support Oncol, 2005; 3(5):349–359.
10.
O’DonnellJF. Insomnia in cancer patients. Clin Cornerstone, 2004; 6(Suppl 1D):S6–S14.
11.
KrauseAJ, PratherAA, WagerTD, et al.The pain of sleep loss: A brain characterization in humans. J Neurosci, 2019; 39(12):2291–2300.
12.
CasaultL, SavardJ, IversH, et al.A randomized-controlled trial of an early minimal cognitive-behavioural therapy for insomnia comorbid with cancer. Behav Res Ther, 2015; 67:45–54.
13.
EspieCA, MacMahonKMA, KellyH-L, et al.Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep, 2007; 30(5):574–584.
14.
GaoY, LiuM, YaoL, et al.Cognitive behavior therapy for insomnia in cancer patients: A systematic review and network meta-analysis. J Evid Based Med, 2022; 15(3):216–229.
15.
GrassiL, ZachariaeR, CarusoR, et al.Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline. ESMO Open, 2023; 8(6):102047; doi: 10.1016/j.esmoop.2023.102047
16.
Kotlinska-LemieszekA, PaulsenO, KaasaS, et al.Polypharmacy in patients with advanced cancer and pain: A European cross-sectional study of 2282 patients. J Pain Symptom Manage, 2014; 48(6):1145–1159.
17.
HowellD, OliverTK, Keller-OlamanS, et al.Sleep disturbance in adults with cancer: A systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol, 2014; 25(4):791–800.
18.
JakobsenG, SjueK, PaulsenO, et al.Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer-a double-blind, randomized placebo-controlled clinical multicenter phase IV trial. Support Care Cancer, 2022; 31(1):60.
19.
JakobsenG, EngstromM, PaulsenO, et al.Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer: Study protocol for a double-blind, randomized, placebo-controlled, clinical multicenter trial. Trials, 2018; 19(1):707.
20.
ChenWY, Giobbie-HurderA, GantmanK, et al.A randomized, placebo-controlled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes. Breast Cancer Res Treat, 2014; 145(2):381–388.
21.
HansenMV, MadsenMT, AndersenLT, et al.Effect of melatonin on cognitive function and sleep in relation to breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Int J Breast Cancer, 2014; 2014:416531.
22.
PalmerACS, ZorteaM, SouzaA, et al.Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. PLoS One, 2020; 15(4):e0231379.
23.
KurdiMS, MuthukalaiSP. The efficacy of oral melatonin in improving sleep in cancer patients with insomnia: A randomized double-blind placebo-controlled study. Indian J Palliat Care, 2016; 22(3):295–300.
24.
JacobsenPB, MassieMJ, KinneDW, et al.Hypnotic efficacy and safety of triazolam administered during the postoperative period. Gen Hosp Psychiatry, 1994; 16(6):419–425.
25.
DimsdaleJE, BallED, CarrierE, et al.Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Support Care Cancer, 2011; 19(12):2015–2020.
26.
ShahrokhiM, GhaeliP, AryaP, et al.Comparing the effects of melatonin and zolpidem on sleep quality, depression, and anxiety in patients with colorectal cancer under going chemotherapy. Basic Clin Neurosci, 2021; 12(1):105–114.
27.
BushSH, LawlorPG, RyanK, et al.ESMO Guidelines Committee. Delirium in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol, 2018; 29(Suppl 4):iv143–iv165.
28.
CentenoC, SanzA, BrueraE. Delirium in advanced cancer patients. Palliat Med, 2004; 18(3):184–194.
29.
LemoineP, NirT, LaudonM, et al.Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res, 2007; 16(4):372–380.
30.
WadeAG, FordI, CrawfordG, et al.Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes. Curr Med Res Opin, 2007; 23(10):2597–2605.
31.
LuthringerR, MuzetM, ZisapelN, et al.The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol, 2009; 24(5):239–249.
32.
ZisapelN. Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: Efficacy and safety in patients with history of use and non-use of hypnotic drugs. Harefuah, 2009; 148(5):337–341, 348.
33.
2023 Therapeutic guidelines limited. ISSN 2653-2557. Psychotropic: Insomnia in adults: Pharmacological treatment for insomnia in adults. Available from https://tgldcdp.tg.org.au.acs.hcn.com.au/
34.
SavardMH, SavardJ, SimardS, et al.Empirical validation of the insomnia severity index in cancer patients. Psychooncology, 2005; 14(6):429–441.
35.
MorinCM, BellevilleG, BelangerL, et al.The insomnia severity index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 2011; 34(5):601–608.
36.
GroenvoldM, PetersenMA, AaronsonNK, et al.EORTC QLQ-C15-PAL: The new standard in the assessment of health-related quality of life in advanced cancer? Palliat Med, 2006; 20(2):59–61.
37.
AkerstedtT, GillbergM. Subjective and objective sleepiness in the active individual. Int J Neurosci, 1990; 52(1–2):29–37.
SchulzKF, AltmanDG, MoherD, Group C. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 2010; 340:c332.
40.
HolbrookAM, CrowtherR, LotterA, et al.Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ, 1999; 160(5):649–655.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
